Emyria Receives positive initial MDMA-analogue screening results
- Emyria (EMD) receives positive results from the first batch of MDMA analogues screened for neuroreceptor activity from pharmaceutical development company, Eurofin
- Results highlighted novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations
- The company says the early results are promising, with very few compounds excluded due to possible off-target concerns at the test concentrations
- A second batch of compounds from the original analogue library is now being prepared for initial screening
- The company is up 6.67 per cent, trading at 40 cents at 1:40 pm AEDT
